# HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

> **NCT06594445** · PHASE1 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 45 (estimated)

## Conditions studied

- Myeloid Malignancy
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** GTB-360

## Key facts

- **NCT ID:** NCT06594445
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-19
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594445, "HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06594445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*